Trastuzumab
- Generic Name
- Trastuzumab
- Brand Names
- Herceptin, Herceptin Hylecta, Herzuma, Kanjinti, Ontruzant, Perjeta-Herceptin, Phesgo, Trazimera, Herwenda, Ogivri, Zercepac, Tuznue
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 180288-69-1
- Unique Ingredient Identifier
- P188ANX8CK
- Background
Produced in CHO cell cultures, trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein (HER2). It is used as a treatment of human epidermal growth factor receptor (HER)-2+ metastatic bre...
- Indication
For the adjuvant treatment of HER2-overexpressing breast cancer, trastuzumab is indicated in several clinical settings: as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel; as part of a treatment regimen with docetaxel and carboplatin; or as monotherapy following multi-modality anthracycline-based th...
- Associated Conditions
- Breast Cancer, Inflammatory Breast Cancer (IBC), Locally Advanced Breast Cancer (LABC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Adenocarcinoma of the Stomach, Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Stage I Breast Cancer
- Associated Therapies
- -
A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020
- Conditions
- Interventions
- First Posted Date
- 2022-05-23
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Vall d'Hebron Institute of Oncology
- Target Recruit Count
- 20
- Registration Number
- NCT05385705
- Locations
- 🇪🇸
Vall d'Hebron Hospital, Barcelona, Spain
🇪🇸Hospital del Mar, Barcelona, Spain
Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-05-18
- Last Posted Date
- 2024-12-06
- Target Recruit Count
- 28
- Registration Number
- NCT05378464
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
Tucatinib Combined With Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study
- Conditions
- Interventions
- First Posted Date
- 2022-05-02
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Academic and Community Cancer Research United
- Registration Number
- NCT05356897
- Locations
- 🇺🇸
UC San Diego Moores Cancer Center, San Diego, California, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab
- Conditions
- Interventions
- First Posted Date
- 2022-04-13
- Last Posted Date
- 2024-08-09
- Target Recruit Count
- 53
- Registration Number
- NCT05325632
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients with ADvanced Human Epidermal Growth Factor Receptor 2+ BrEast Cancer with the Addition of Tucatinib
- First Posted Date
- 2022-04-12
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Carey Anders, M.D.
- Target Recruit Count
- 48
- Registration Number
- NCT05323955
- Locations
- 🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸University of Michigan Health System, Ann Arbor, Michigan, United States
A Study of Trastuzumab and Pyrotinib in HER2 Positive Locally Advanced or Metastatic Urothelial Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-04-08
- Last Posted Date
- 2022-04-08
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 30
- Registration Number
- NCT05318339
- Locations
- 🇨🇳
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-02-24
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 400
- Registration Number
- NCT05253651
- Locations
- 🇺🇸
Palo Verde Cancer Specialists, Glendale, Arizona, United States
🇺🇸Mayo Clinic Arizona, Phoenix, Arizona, United States
🇺🇸Pacific Cancer Medical Center, Anaheim, California, United States
SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-02-01
- Last Posted Date
- 2022-04-06
- Lead Sponsor
- Aiping Zhou
- Target Recruit Count
- 44
- Registration Number
- NCT05218148
- Locations
- 🇨🇳
Cancer Hospital & Institute, Chinese Academy of Medical Sciences, Beijing, China
CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
- First Posted Date
- 2022-01-26
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Celularity Incorporated
- Target Recruit Count
- 1
- Registration Number
- NCT05207722
- Locations
- 🇺🇸
Georgetown, Washington, District of Columbia, United States
🇺🇸John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Scripps Health, La Jolla, California, United States
Camrelizumab Combined With Trastuzumab and Chemotherapy in Patients With HER2-positive Advanced Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-01-14
- Last Posted Date
- 2022-01-14
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 77
- Registration Number
- NCT05193292
- Locations
- 🇨🇳
270 Dongan Road, Fudan University Shanghai Cancer Center, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.